The stock of TNF Pharmaceuticals Inc (TNFA) has seen a -13.81% decrease in the past week, with a -24.88% drop in the past month, and a -65.57% decrease in the past quarter. The volatility ratio for the week is 15.48%, and the volatility levels for the past 30 days are at 17.18% for TNFA. The simple moving average for the last 20 days is -18.26% for TNFA stock, with a simple moving average of -85.05% for the last 200 days.
Is It Worth Investing in TNF Pharmaceuticals Inc (NASDAQ: TNFA) Right Now?
The price-to-earnings ratio for TNF Pharmaceuticals Inc (NASDAQ: TNFA) is above average at N/Ax. The 36-month beta value for TNFA is also noteworthy at 2.00. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The average price estimated by analysts for TNFA is N/A, which is -$4719968.0 below than the current price. The public float for TNFA is 13.48M, and at present, short sellers hold a 26.70% of that float. The average trading volume of TNFA on July 01, 2025 was 4.72M shares.
TNFA) stock’s latest price update
TNF Pharmaceuticals Inc (NASDAQ: TNFA)’s stock price has gone decline by -1.87 in comparison to its previous close of 0.12, but the company has seen a -13.81% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-06-24 that NEW YORK–(BUSINESS WIRE)—- $TNFA–TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it has formed a philanthropic collaboration with the DADA2 Foundation, a nonprofit organization seeking innovative ways to accelerate research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2). Together, the parties are expected.
Analysts’ Opinion of TNFA
Many brokerage firms have already submitted their reports for TNFA stocks, with N/A repeating the rating for TNFA by listing it as a “N/A.” The predicted price for TNFA in the upcoming period, according to N/A is N/A based on the research report published on N/A of the N/A year N/A.
N/A, on the other hand, stated in their research note that they expect to see TNFA reach a price target of N/A. The rating they have provided for TNFA stocks is “N/A” according to the report published on N/A.
N/A gave a rating of “N/A” to TNFA, setting the target price at N/A in the report published on N/A of the N/A year.
TNFA Trading at -29.72% from the 50-Day Moving Average
After a stumble in the market that brought TNFA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.42% of loss for the given period.
Volatility was left at 17.18%, however, over the last 30 days, the volatility rate increased by 15.48%, as shares sank -28.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.57% lower at present.
During the last 5 trading sessions, TNFA fell by -12.95%, which changed the moving average for the period of 200-days by -91.93% in comparison to the 20-day moving average, which settled at $0.1475. In addition, TNF Pharmaceuticals Inc saw -93.42% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TNFA starting from N/A, who N/A N/A shares at the price of N/A back on N/A. After this action, N/A now owns N/A shares of TNF Pharmaceuticals Inc, valued at N/A using the latest closing price.
N/A, the N/A of TNF Pharmaceuticals Inc, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for TNFA
Current profitability levels for the company are sitting at:
- N/A for the present operating margin
- N/A for the gross margin
The net margin for TNF Pharmaceuticals Inc stands at N/A. The total capital return value is set at -0.69. Equity return is now at value -121.95, with -88.26 for asset returns.
Based on TNF Pharmaceuticals Inc (TNFA), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -848.51. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is N/A.
Currently, EBITDA for the company is -23.36 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of N/A. The receivables turnover for the company is N/Afor trailing twelve months and the total asset turnover is N/A. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.37.
Conclusion
In summary, TNF Pharmaceuticals Inc (TNFA) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
